Technical Analysis for BLTE - Belite Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 45.82 | 0.31% | 0.14 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | 0.31% | |
| NR7 | Range Contraction | 0.31% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 2 % | 3 days ago |
| Possible NR7 | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Belite Bio, Inc. Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy Stargardt Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.15 |
| 52 Week Low | 12.53 |
| Average Volume | 57,325 |
| 200-Day Moving Average | 41.50 |
| 50-Day Moving Average | 44.86 |
| 20-Day Moving Average | 48.54 |
| 10-Day Moving Average | 47.95 |
| Average True Range | 1.52 |
| RSI (14) | 39.39 |
| ADX | 24.63 |
| +DI | 11.96 |
| -DI | 29.93 |
| Chandelier Exit (Long, 3 ATRs) | 45.59 |
| Chandelier Exit (Short, 3 ATRs) | 49.57 |
| Upper Bollinger Bands | 50.99 |
| Lower Bollinger Band | 46.09 |
| Percent B (%b) | -0.06 |
| BandWidth | 10.09 |
| MACD Line | 0.33 |
| MACD Signal Line | 1.02 |
| MACD Histogram | -0.6889 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.90 | ||||
| Resistance 3 (R3) | 46.83 | 46.41 | 46.72 | ||
| Resistance 2 (R2) | 46.41 | 46.13 | 46.44 | 46.66 | |
| Resistance 1 (R1) | 46.11 | 45.96 | 45.90 | 46.18 | 46.60 |
| Pivot Point | 45.69 | 45.69 | 45.58 | 45.72 | 45.69 |
| Support 1 (S1) | 45.39 | 45.41 | 45.18 | 45.46 | 45.04 |
| Support 2 (S2) | 44.97 | 45.24 | 45.00 | 44.98 | |
| Support 3 (S3) | 44.67 | 44.97 | 44.92 | ||
| Support 4 (S4) | 44.74 |
